Perspectives on vaccination in adults

References

• Rodgers GL, Klugman KP. The future of pneumococcal disease prevention. Vaccine 29(Suppl. 3), C43–C48 (2011).
   Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O. Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs Aging 30(5), 263–276 (2013).
   PubMedGoogle Scholar
• Levine H, Balicer RD, Zarka S et al. Dynamics of pneumococcal acquisition and carriage in young adults during training in confined settings in Israel. PLoS ONE 7(10), e46491 (2012).
   PubMed Web of Science ®Google Scholar
• Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int. J. Antimicrob. Agents 32(3), 199–206 (2008).
   PubMed Web of Science ®Google Scholar
• McIntosh ED, Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev. Vaccines 10(1), 109–129 (2011).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Plikaytis BD, Akkoyunlu M et al. Establishment of a new human pneumococcal standard reference serum, 007sp. Clin. Vaccine Immunol. 18(10), 1728–1736 (2011).
   PubMed Web of Science ®Google Scholar
• Rose M, Buess J, Ventur Y et al. Reference ranges and cut off levels of pneumococcal antibody global serum assays (IgG & IgG2) and specific antibodies in healthy children and adults. Med. Microbiol. Immunol. (2013) (In Press).
   Google Scholar
• Welte T. How can we reduce the mortality of invasive pneumococcal disease? Eur. Respir. Rev. 21(123), 6–7 (2012).
   Google Scholar
• Dagan R, Bhutta ZA, de Quadros CA et al. The remaining challenge of pneumonia: the leading killer of children. Pediatr. Infect. Dis. J. 30(1), 1–2 (2011).
   Google Scholar
• Michaelis M, Doerr HW, Cinatl J Jr. An influenza A H1N1 virus revival – pandemic H1N1/09 virus. Infection 37(5), 381–389 (2009).
   PubMed Web of Science ®Google Scholar
• Reperant LA, Kuiken T, Osterhaus AD. Adaptive pathways of zoonotic influenza viruses: from exposure to establishment in humans. Vaccine 30(30), 4419–4434 (2012).
   PubMed Web of Science ®Google Scholar
• Michaelis M, Doerr HW, Cinatl J Jr. Of chickens and men: avian influenza in humans. Curr. Mol. Med. 9(2), 131–151 (2009).
   PubMed Web of Science ®Google Scholar
• Drosten C, Preiser W, Günther S, Schmitz H, Doerr HW. Severe acute respiratory syndrome: identification of the etiological agent. Trends Mol. Med. 9(8), 325–327 (2003).
   Google Scholar
• Cinatl J Jr, Michaelis M, Hoever G, Preiser W, Doerr HW. Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Res. 66(2–3), 81–97 (2005).
   PubMed Web of Science ®Google Scholar
• Mörner A, Bråve A, Kling AM et al. Pandemic influenza A(H1N1)pdm09 seroprevalence in Sweden before and after the pandemic and the vaccination campaign in 2009. PLoS ONE 7(12), e53511 (2012).
   Google Scholar
• Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a Phase II randomized, controlled trial of immunogenicity and safety in healthy adults. J. Infect. Dis. 203(12), 1719–1728 (2011).
   PubMedGoogle Scholar
• Banzhoff A, Stoddard JJ. Effective influenza vaccines for children: a critical unmet medical need and a public health priority. Hum. Vaccin. Immunother. 8(3), 398–402 (2012).
   PubMedGoogle Scholar
• Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane MA. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine 30(Suppl. 5), F1–F11 (2012).
   PubMedGoogle Scholar
• Stöcker P, Dehnert M, Schuster M, Wichmann O, Deleré Y. Human papillomavirus vaccine uptake, knowledge and attitude among 10th grade students in Berlin, Germany, 2010. Hum. Vaccin. Immunother. 9(1), 74–82 (2013).
   PubMed Web of Science ®Google Scholar
• Ljungman P. Vaccination of immunocompromised patients. Clin. Microbiol. Infect. 18(Suppl. 5), 93–99 (2012).
   Google Scholar
• Gross G, Doerr HW. Herpes Zoster – Recent Aspects of Diagnosis and Control. Monographs in Virology, Vol. 26. Karger Press, Basel, Switzerland (2006).
   Google Scholar
• Oxman MN. Zoster vaccine: current status and future prospects. Clin. Infect. Dis. 51(2), 197–213 (2010).
   PubMed Web of Science ®Google Scholar
• Goldman GS, King PG. Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost–effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data. Vaccine 31(13), 1680–1694 (2013).
   PubMed Web of Science ®Google Scholar
• O’Connell RJ, Kim JH, Corey L, Michael NL. Human immunodeficiency virus vaccine trials. Cold Spring Harb. Perspect. Med. 2(12), a007351 (2012).
   PubMedGoogle Scholar
• Pegu P, Vaccari M, Gordon S et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J. Virol. 87(3), 1708–1719 (2013).
   PubMed Web of Science ®Google Scholar
• Eberle J, Gürtler L. HIV types, groups, subtypes and recombinant forms: errors in replication, selection pressure and quasispecies. Intervirology 55(2), 79–83 (2012).
   Google Scholar
• Doherty TM. Immunotherapy for TB. Immunotherapy 4(6), 629–647 (2012).
   PubMed Web of Science ®Google Scholar
• Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog. 8(5), e1002607 (2012).
   PubMed Web of Science ®Google Scholar
• Ottenhoff TH. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol. 20(9), 419–428 (2012).
   PubMed Web of Science ®Google Scholar
• Anderson AS, Miller AA, Donald RG et al. Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum. Vaccin. Immunother. 8(11), 1585–1594 (2012).
   PubMed Web of Science ®Google Scholar
• Pozzi C, Wilk K, Lee JC, Gening M, Nifantiev N, Pier GB. Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens. PLoS ONE 7(10), e46648 (2012).
   PubMedGoogle Scholar
• Gerding DN. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. Discov. Med. 13(68), 75–83 (2012).
   PubMed Web of Science ®Google Scholar
• von Müller L, Halfmann A, Herrmann M. [Current data and trends on the development of antibiotic resistance of Clostridium difficile]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55(11–12), 1410–1417 (2012).
   Google Scholar
• Pacheco SM, Johnson S. Important clinical advances in the understanding of Clostridium difficile infection. Curr. Opin. Gastroenterol. 29(1), 42–48 (2013).
   PubMedGoogle Scholar
• Doerr W. Arteriosclerosis without end. Principles of pathogenesis and an attempt at a nosologic classification. Virchows Arch. A. Pathol. Anat. Histol. 380(2), 91–106 (1978).
   Google Scholar
• Salazar-González JA, Rosales-Mendoza S. A perspective for atherosclerosis vaccination: is there a place for plant-based vaccines? Vaccine 31(10), 1364–1369 (2013).
   PubMed Web of Science ®Google Scholar
• Bhakdi S, Lackner K, Doerr HW. Possible hidden hazards of mass vaccination against new influenza A/H1N1: have the cardiovascular risks been adequately weighed? Med. Microbiol. Immunol. 198(4), 205–209 (2009).
   Google Scholar
• Raupach T, Hoogsteder PH, Onno van Schayck CP. Nicotine vaccines to assist with smoking cessation: current status of research. Drugs 72(4), e1–e16 (2012).
   PubMedGoogle Scholar
• Regev-Yochay G, Raz M, Dagan R et al. Reduction in antibiotic use following a cluster randomized controlled multifaceted intervention: the Israeli judicious antibiotic prescription study. Clin. Infect. Dis. 53(1), 33–41 (2011).
   PubMed Web of Science ®Google Scholar